MoonLake Immunotherapeutics
MLTX
MLTX
46 hedge funds and large institutions have $113M invested in MoonLake Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Holders
46
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.07M | |
| 2 | +$725K | |
| 3 | +$588K | |
| 4 |
PCM
Prelude Capital Management
New York
|
+$518K |
| 5 |
Millennium Management
New York
|
+$370K |
Top Sellers
| 1 | -$1.55M | |
| 2 | -$613K | |
| 3 | -$372K | |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$361K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$108K |